Vanderbilt Center for Antibody Therapeutics (VCAT)

Vaccine researchers ready as new flu strain evolves

A worrisome new avian influenza virus, called H7N9, emerged this spring in Eastern China.

VU researchers ‘goldsmith’ new RSV vaccine approach

Vanderbilt vaccine researchers are using gold nanotechnology to develop a new approach to making vaccines.

Study lays groundwork for rational T cell vaccine design

Vanderbilt University investigators have developed a new strategy for identifying the “bits” of a pathogen that spark a protective immune response.

Grant targets new therapies for Ebola, Marburg viruses

Vanderbilt’s James Crowe Jr., M.D., and a collaborator in Texas have been awarded a $4.4 million grant from the U.S. Department of Defense to study new ways to treat and prevent Ebola and Marburg viruses.

Symposium to offer look at latest infectious diseases imaging research

The latest research on imaging infectious diseases will be discussed during a mini-symposium noon to 5 p.m., April 12, at the Vanderbilt Student Life Center Board of Trust Room.

Structural snapshot hints at new influenza approach

A careful look at how the body’s natural defenses disarm virulent strains of influenza hints at the possibility of a way to fight the flu.

1 10 11 12 13 14